Ergoteles’s Design Therapeutics DSGN Stock Holding History

Ergoteles’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-177,337	Closed	-$1.02M	–	1141
2023 Q1	$1.02M	Buy	+177,337	New	+$1.33M	0.04%	493

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Ergoteles's DSGN Position: Q2 2023 in Review

Ergoteles sold out of Design Therapeutics (DSGN) in Q2 2023, closing a stake of 177,337 shares — an estimated $1.02M sold.

Ergoteles first reported a position in DSGN in Q1 2023 and held it in 1 quarter. The position peaked at $1.02M in Q1 2023. 97 funds tracked by Wall St. Rank hold DSGN as of Q2 2023.

Ergoteles reported no remaining Design Therapeutics position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 177,337 Design Therapeutics shares in Q2 2023, an estimated $1.02M.
Ergoteles first reported a position in Design Therapeutics in Q1 2023 and held it in 1 quarter.
Ergoteles's Design Therapeutics position peaked at $1.02M in Q1 2023.
97 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.